COO

Business profile & competitive position

The Cooper Companies, Inc. operates in the Healthcare sector under the Medical - Instruments & Supplies industry classification. The business is split into two global franchises: CooperVision and CooperSurgical. CooperVision develops, manufactures and markets contact lenses spanning single-use, two-week and monthly modalities, including silicone hydrogel lenses, myopia-management products such as the MiSight 1 day lens, orthokeratology lenses and scleral lenses. CooperSurgical provides more than 600 products and services concentrated on fertility and women’s health, spanning gynecology, obstetrics, contraception, labor and delivery, cord blood and tissue storage, IVF support, donor gametes, cryopreservation and genomic services. Products are sold in over 130 countries, and the company reports that its products reach more than 50 million lives annually.

The margin profile is worth reading carefully rather than taking at face value as a wide-moat signal. Net margin is 13.5%, which is healthy for a medical-devices distribution and manufacturing operation, and the company carries a roughly 500-person combined R&D organization across both segments. ROE, however, is 6.9%. A mid-single-digit ROE is more consistent with a capital-intensive, acquisitive growth model than with a software-like or pharmaceuticals-like compounder. The gap between a respectable net margin and a modest ROE suggests that asset turns and leverage are not returning extraordinary equity yields; capital is being reinvested into distribution infrastructure, myopia-management market development, and CooperSurgical integrations rather than converting into outsized shareholder returns at the equity level. MiSight’s position as the only contact lens approved by the FDA, China’s NMPA and Japan’s MHLW to slow myopia progression in age-appropriate children is a concrete regulatory differentiator, but the favorable margin does not by itself prove pricing power is widening.

Financial posture

At the time of the snapshot, Cooper carried a market capitalization of $10.7 billion and traded at a P/E of 18.7. Those figures sit in the lower-relative-valuation territory for a medical-device growth name, though valuation alone does not indicate direction. Profitability metrics show a 13.5% net margin and 6.9% ROE. The stock’s beta is 0.82, meaning it has historically moved roughly 18% less than the broad market on average, which is typical for defensive, healthcare-oriented cash-flow streams.

Read together, the numbers paint a picture of a profitable but capital-heavy business whose current valuation embeds questions about future growth rather than momentum. A beta below 1.0 and a mid-teens P/E imply the market is treating the company more like a stable healthcare operator than a high-growth disruptor, even as R&D and segment-level expansion continue.

Strategic priorities & outlook

The company’s most recent 10-K filing outlined specific operational priorities for each segment. CooperVision is focused on driving worldwide market penetration of recently introduced products and expanding its presence in existing and emerging markets. It is also increasing investment in distribution and packaging capabilities to support growth and service quality, and it is investing to develop the myopia-management market by educating eye care practitioners, patients and their families. On the CooperSurgical side, the company expects to continue investing in the business, including through strategic transactions, to expand its integrated solutions model within fertility and women’s health.

Those priorities imply a strategy that leans more on distribution scale, regulatory-cleared myopia products, and bolt-on fertility/women’s health acquisitions than on a single blockbuster pipeline. Emerging-market expansion and practitioner education around myopia are multi-year initiatives; CooperSurgical’s “integrated solutions” push suggests ongoing capital deployment into an acquisition-heavy segment. That fits the modest ROE read: returns are being reinvested rather than harvested.

Macro & geopolitical exposure

As a Medical - Instruments & Supplies company, Cooper sits at the intersection of healthcare regulation, global distribution and demographic health trends. Contact lenses and women’s-health devices are subject to FDA and foreign-regulator approvals, quality inspections, reimbursement negotiations, and evolving healthcare policy. A global footprint spanning more than 130 countries creates currency exposure: a stronger U.S. dollar weighs on translated overseas revenue, while a weaker dollar has the opposite effect. The industry also faces supply-chain sensitivities around polymers, packaging and sterile manufacturing capacity, and trade-policy shifts can alter landed costs for components and finished goods.

Demographics cut both ways. Myopia prevalence is rising globally, supporting CooperVision’s educational and product expansion strategy, while fertility trends and macroeconomic uncertainty can influence CooperSurgical utilization. Unlike commodity-driven healthcare names, Cooper’s exposure is less about raw-material prices and more about regulatory compliance, reimbursement rates, cross-border logistics and discretionary or deferrable procedure volumes in fertility and women’s health.

Recent developments

On September 18, 2026, three separate headlines from Reuters, Barron’s and PR Newswire reported that activist investor JANA Partners is pressing Cooper’s board to replace the chief executive officer and evaluate asset sales after performance setbacks. That same day, PR Newswire carried a separate securities-investigation notice from Levi & Korsinsky regarding Cooper Companies. The clustering of activist pressure and a law-firm investigation notice on the same date is unusual and frames the stock’s September trading environment around governance, leadership and portfolio-composition questions rather than purely around fundamental earnings.

At the snapshot date of September 21, 2026, the stock price was $54.79, the RSI was 24.9 — a reading generally associated with oversold conditions — and the 50-day exponential moving average sat at $66.67, meaning the price was trading roughly 18% below that short-to-intermediate trend measure. The combination of activist news, the investigation notice and the sharp technical deterioration provides the context within which the upcoming earnings report will be read.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, Cooper has beaten consensus earnings-per-share estimates in every single quarter, for a 100% beat rate, with an average earnings surprise of 4.2%. That is a strong headline record. Yet the average five-day post-earnings price move has been -2.34%, classified as a downward drift. The mismatch between consistent beats and negative average follow-through is the central lesson for anyone studying this stock around releases: beating the estimate has not reliably translated into a higher stock price over the subsequent week.

The most recent quarterly results make that point explicitly. On September 9, 2026, Cooper reported EPS of $1.15 against an estimate of $1.12, a 2.7% positive surprise, but the stock fell 14.67% the next day and 13.97% over the following five days — one of the most violent negative reactions in the set despite a beat. The prior three quarters showed the same beat-every-time pattern but delivered mixed price performance:

• June 4, 2026: EPS of $1.21 versus $1.10 estimate, a 10.0% surprise, with the stock rising 8.58% the next day and 8.85% over five days.
• March 5, 2026: EPS of $1.10 versus $1.03 estimate, a 6.8% surprise, yet the stock fell 4.55% the next day and 10.82% over five days.
• December 4, 2025: EPS of $1.15 versus $1.11 estimate, a 3.6% surprise, with the stock rising 5.67% the next day and 6.59% over five days.

Three of the four most recent beats produced next-day gains, but the September 2026 release was so decisive to the downside that the average five-day drift across all recent quarters remains negative. The next scheduled report is December 3, 2026 after the market close, with a consensus EPS estimate of $1.08. Given the 100% beat rate, the market’s real expectation may be something closer to the historical $0.04–$0.11 beat range, but the price reaction will likely depend more on guidance, strategic clarity and any update on the activist situation than on the EPS headline alone.

For readers who want to move beyond the raw data, the full institutional verdict — covering analyst rating distributions, revision trends, target dispersion and fund-flow context — is the natural next stop. It places the 100% beat rate, the -2.34% average post-earnings drift, and the September governance headlines into a broader market narrative.